Karyopharm downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a “rocky regulatory road” forward for the company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.